Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

NCT02956486 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT02956486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02956486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
October 20, 2016
Completion date
January 15, 2020
Enrollment
2,212 (actual)
Sites
258

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease